Celecoxib-Induced Apoptosis in Rat Cholangiocarcinoma Cells Mediated by Akt Inactivation and Bax Translocation

Hepatology

Volumn 39, Issue 4, 2004, Pages 1028-1037

  Zhang, Zichen ^a   Lai, Guan Hua ^a   Sirica, Alphonse E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CASPASE 9; CELECOXIB; CYCLOOXYGENASE 2; CYTOCHROME C; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROSTAGLANDIN E2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; ROFECOXIB;

ANIMAL CELL; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; MALE; NEOPLASM TRANSPLANTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; RATS; RATS, INBRED F344; SULFONAMIDES;

EID: 1842584647     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20143     Document Type: Article

References (28)

1. Sirica AE, Lai G-H, Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 2001;16:363-372.
2. Sirica AE, Lai G-H, Endo K, Zhang Z, Yoon B. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 2002;22:303-313.
3. Sirica AE. Bile duct cancer, ERBB-2, and COX-2. Sci Med 2002;8:268-277.
4. Chariyalertsak S, Sirikulchayanonta V, Mayer D, Kopp-Schneider A, Furstenberger G, Marks F, Muller-Decker K. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut 2001; 48:80-86.
5. Hayashi N, Yamamoto H, Hiraoka N, Dono K, Ito Y, Okami J, Kondo M, et al. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. HEPATOLOGY 2001;34:638-650.
6. Endo K, Yoon B, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cydooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. HEPATOLOGY 2002;36:439-450.
7. Lai G-H, Sirica AE. Establishment of a novel rat cholangiocarcinoma cell culture model. Carcinogenesis 1999;20:2335-2339.
8. Lai G-H, Zhang Z, Sirica AE. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and-3. Mol Cancer Ther 2003;2:265-271.
9. 2 and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. HEPATOLOGY 2002;36:363-373.
10. Sirica AE. Bile duct epithelial cell culture. In: Wise C, ed. Methods in Molecular Biology. Epithelial Cell Culture Protocols; vol 188. Totowa, NJ: Humana Press, 2002:37-52.
11. Radaeva S, Ferreira-Gonzalez A, Sirica AE. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. HEPATOLOGY 1999;29:1453-1462.
12. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001;61: 7196-7203.
13. 2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol 2003;9:1302-1306.
14. Yamazaki R, Kusunoki N, Matsuzaki T, Hasimoto S, Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002; 531:278-284.
15. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002;62:2029-2033.
16. Zhu J, Song X, Lin H-P, Young DC, Yan S, Marquez VE, Chen C-S. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 2002; 94:1745-1757.
17. Patti R, Gumired K, Reddanna P, Sutton LN, Phillips PC, Reddy CD. Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. Cancer Lett 2002; 180:13-21.
18. Hsu A-L, Ching T-T, Wang D-S, Song X, Rangnekar VM, Chen C-S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-11403.
19. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. HEPATOLOGY 2003;38:756-768.
20. Li M, Wu X, Xu X-C. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clinical Cancer Res 2001;7:1010-1016.
21. Sun Y, Ming Tang X, Half E, Tien Kuo M, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 2002;62:6323-6328.
22. Yamaguchi H, Wang H-G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational changes. Oncogene 2001;20:7779-7786.
23. Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem 2002;277:14040-14047.
24. Kern MA, Schubert D, Sahi D, Schoneweiss MM, Moll I, Haugg AM, Dienes HP, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. HEPATOLOGY 2002;36:885-894.
25. Totzke G, Schulze-Osthoff K, Janicke RU. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 2003;22: 6077-6086.
26. 2. J Biol Chem 2002; 277:2614-2619.
27. 2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003;278:12151-12156.
28. Nzeako UC, Guicciardi ME, Yoon J-H, Bronk SF, Gores GJ. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. HEPATOLOGY 2002;35:552-559.